Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381208 | 0.76 | ANPEP (0.45) | MEN1KMT2AALDH1A1POLBLMNA | |
| SCHEMBL27765709 | 0.74 | NOTUM (0.51) | MEN1KMT2AALDH1A1POLBLMNA | |
| SCHEMBL21225774 | 0.73 | MYC (0.58) | NPSR1MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL1860045 | 0.72 | NPSR1 (0.40) | NPSR1MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL21225558 | 0.70 | ALDH1A1 (0.55) | NPSR1MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL18586193 | 0.70 | ALDH1A1 (0.55) | NPSR1MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL18799989 | 0.68 | POLB (0.40) | POLBLMNA | |
| SCHEMBL24759727 | 0.68 | POLB (0.37) | ALDH1A1POLBLMNA | |
| SCHEMBL4389760 | 0.68 | APLNR (0.54) | ALDH1A1POLBGAA | |
| SCHEMBL4376341 | 0.67 | MAPK14 (0.42) | POLBLMNANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426426-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110104207-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-05 | — | — | US | disclosed |
| US-7727992-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100105701-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2010-04-29 | — | — | US | disclosed |
| EP-1511482-B1 | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1511482-A1 | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003105846-A1 | 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105701-A1 | GYRASE INHIBITORS AND USES THEREOF | GMPS, NQO2, TOP1 | NPSR1 4847/4885MEN1 4087/4885KMT2A 2852/4885 |
| US-20110104207-A1 | GYRASE INHIBITORS AND USES THEREOF | GMPS, NQO2, TOP1 | NPSR1 4847/4885MEN1 4087/4885KMT2A 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.